Pearsanta, Inc., a subsidiary of Aditxt Inc., has engaged Spartan Capital Securities, LLC as the lead underwriter for its planned Initial Public Offering $(IPO.UK)$. This move aligns with Aditxt's "Acquire, Build, and Capitalize" strategy, aiming to accelerate the growth of innovative health companies. The IPO is intended to support the clinical validation and commercial rollout of Pearsanta's Mitomic™ platform technology, designed for the early detection of cancers and other diseases. Pearsanta's mission is to offer proactive, personalized care by identifying diseases at their earliest and most treatable stages, thereby saving lives and reducing the emotional and financial toll on families and healthcare systems.